Transactions detail
Patrick Plewman, who serves as senior vice president for Diagnostic Services at Quest Diagnostics Inc. (NYSE: DGX), sold 2,855 shares of the company's common stock on March 5, 2026. The disposition generated proceeds of $588,729, with the shares selling at $206.21 each. That sale was carried out under a Rule 10b5-1 sales plan.
These market moves came while the stock was trading close to its 52-week high of $213.50 and after its year-to-date performance showed an 18% gain.
Related stock award and withholding
The day before the sale, on March 4, 2026, Plewman received 5,682 Quest Diagnostics common shares as the result of the settlement of a performance stock award. Those shares were valued at $1,164,014 based on a per-share price of $204.86.
Also on March 4, 2026, Plewman had 2,827 shares disposed of to cover tax withholding obligations. The withheld shares were valued at $579,139 at the same per-share price of $204.86.
After the sequence of the award settlement, the tax-withholding disposition, and the Rule 10b5-1 sale, Plewman directly owns 15,198 shares of Quest Diagnostics Inc.
Valuation, dividend track and company sizing
According to InvestingPro analysis cited in company coverage, Quest Diagnostics currently appears overvalued on a Fair Value assessment. The coverage notes that the company has raised its dividend for 14 consecutive years. That dividend streak is listed as one of multiple ProTips available to subscribers, alongside in-depth Pro Research Reports covering the company—characterized in the analysis as a $21.94 billion healthcare diagnostics leader.
Recent corporate developments
In other recent updates, Quest Diagnostics reported fourth-quarter results for 2025 that exceeded analyst expectations. The company posted earnings per share of $2.42, versus a consensus forecast of $2.36, and reported revenue of $2.81 billion compared with an expected $2.75 billion.
Quest also introduced the Quest AI Companion, an AI-powered capability that allows users to review and analyze their laboratory test results through the MyQuest mobile app and patient portal. The tool, which uses Google’s Gemini models, provides explanations for test results and can analyze up to five years of lab data.
Additionally, Quest Diagnostics appointed Benjamin Beauvalot as senior vice president, chief strategy and M&A officer. Beauvalot is reported to bring more than 20 years of experience in business strategy, mergers and acquisitions, and transformation from his prior role at Danaher Corporation.
Context and takeaway
The set of transactions by Plewman combined an award settlement, routine tax-withholding, and a prearranged sale under a Rule 10b5-1 plan, leaving him with direct ownership of 15,198 shares. These moves coincided with the stock trading near its yearly high and followed a quarter in which Quest Diagnostics beat top- and bottom-line Street expectations. InvestingPro commentary referenced in coverage suggests the stock is trading above its Fair Value estimate and highlights the company’s multi-year record of dividend increases.